Want to see XERS full AI Analyst Report?
XERS Stock Chart & Stats
$8.74
$0.03(0.36%)
At close: 4:00 PM EDT
$8.74
$0.03(0.36%)
Day’s Range― - ―
52-Week Range$5.25 - $10.08
Previous CloseN/A
Volume106.69K
Average Volume (3M)1.69M
Market Cap
$1.50B
Enterprise Value$1.54K
Total Cash (Recent Filing)$121.75M
Total Debt (Recent Filing)$289.44M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Nov 05, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding182,320,310
10 Day Avg. Volume2,080,230
30 Day Avg. Volume1,686,427
Financial Highlights & Ratios
PEG Ratio-22.22
Price to Book (P/B)92.00
Price to Sales (P/S)4.32
P/FCF Ratio45.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$12.67Price Target Upside44.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$387.25M
Bulls Say, Bears Say
Bulls Say
Commercial GrowthBroad-based product growth, led by Recorlev, indicates improving commercial execution across Xeris’s portfolio. Raised and tightened revenue guidance provides a durable operating foundation, while stronger prescription demand can support continued scale over the next several quarters.
Cash Generation And Product EconomicsPositive operating and free cash flow marks a meaningful improvement from negative cash generation in earlier periods. This gives Xeris greater capacity to fund commercialization and development internally, while reducing reliance on external capital as the business expands.
Pipeline And Intellectual PropertyAdvancing XP-8121 toward Phase 3 adds a potentially meaningful growth platform beyond the current products. Its differentiated formulation, patent protection, and planned use of Xeris’s commercial infrastructure could strengthen the company’s long-term market position if development succeeds.
Bears Say
Fragile Balance SheetHigh debt combined with negative equity leaves Xeris with a thin capital cushion and less flexibility to absorb operating setbacks. Although one convertible tranche was retired, the remaining leverage can constrain investment choices and increase dependence on sustained cash generation.
Persistent Net LossesThe company has not yet converted operating progress into consistent bottom-line profitability. Continued net losses can limit internally funded growth, weaken resilience during commercialization fluctuations, and make earnings quality less dependable over the next several quarters.
Higher Investment BurdenGreater commercial and research spending may support future growth, but it also raises the cost base before the pipeline contributes revenue. If product expansion or XP-8121 milestones take longer than planned, elevated expenses could delay sustainable profitability and pressure cash conversion.
Xeris Pharmaceuticals News
XERS FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest stock price was $5.25 and its highest was $10.08 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $1.50B.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 44 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of $0.012 by -$0.192.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is 0.04.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 182,320,310 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of -$0.18 in its last earnings report, missing expectations of $0.012. Following the earnings report the stock price went down -9.248%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in XERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xeris Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.67 (44.93% Upside)
$12.67 (44.93% Upside)
Blogger Sentiment
Bullish
XERS Sentiment 78%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 6.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
XERS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum (notably Recorlev’s 81% YoY growth), improved profitability (86% gross margin, adjusted EBITDA +50% YoY), strategic wins (Keveyis patent protection, retirement of convertible notes) and material pipeline progress for XP-8121 (multiple patents, Phase III planned by year-end). Lowlights were largely manageable: a one-time non-cash GAAP charge of ~$31M, higher near-term SG&A and R&D investments to fund growth and XP-8121, earlier-year softness in Gvoke that has since rebounded, and some remaining timing/enrollment uncertainty around Phase III. Overall, positive commercial execution and balance sheet actions outweigh the near-term charges and increased investment cadence.View all XERS earnings summariesXERS Stock 12 Month Forecast
Average Price Target
$12.67
▲(44.93% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Zymeworks
―
Arcus Biosciences
―
Stoke Therapeutics
―
Rapport Therapeutics, Inc.
―
Ownership Overview
4.92% Insiders
10.49% Mutual Funds
10.46% Other Institutional Investors
60.12% Public Companies and
Individual Investors